(NASDAQ: RLAY) Relay Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 41.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 38.38%.
Relay Therapeutics's earnings in 2026 is -$276,479,000.On average, 13 Wall Street analysts forecast RLAY's earnings for 2026 to be -$290,894,127, with the lowest RLAY earnings forecast at -$401,096,461, and the highest RLAY earnings forecast at -$235,149,547. On average, 9 Wall Street analysts forecast RLAY's earnings for 2027 to be -$278,401,193, with the lowest RLAY earnings forecast at -$376,575,280, and the highest RLAY earnings forecast at -$225,194,519.
In 2028, RLAY is forecast to generate -$278,472,683 in earnings, with the lowest earnings forecast at -$362,563,176 and the highest earnings forecast at -$191,415,341.